Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New drugs; palifermin].

A F Cohen1, E A Dubois, H van Bronswijk

  • 1Centre for Human Drug Research, Zernikedreef 10, 2333 CL Leiden. ac@chdr.nl

Nederlands Tijdschrift Voor Geneeskunde
|January 18, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intubation Rather Than Cardiac Arrest as a Risk-Modifier of Mortality in Infarction-Related Cardiogenic Shock.

Journal of cardiac failure·2026
Same author

Understanding patients with mechanical circulatory support for cardiogenic shock: The role of preceding cardiac arrest.

Resuscitation·2026
Same author

Coronary CT angiography for suspected acute coronary syndrome: sex-associated differences.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2021
Same author

Using machine learning techniques to characterize sleep-deprived driving behavior.

Traffic injury prevention·2021
Same author

Towards remote monitoring in pediatric care and clinical trials-Tolerability, repeatability and reference values of candidate digital endpoints derived from physical activity, heart rate and sleep in healthy children.

PloS one·2021
Same author

The use of machine learning improves the assessment of drug-induced driving behaviour.

Accident; analysis and prevention·2020

Palifermin, a keratinocyte growth factor, effectively prevents oral mucositis in adults undergoing myeloablative therapy. Long-term safety data for this recombinant-DNA-produced growth factor are still pending, with potential adverse effects noted on skin and mucous membranes.

Area of Science:

  • Biotechnology
  • Pharmacology
  • Oncology

Context:

  • Myeloablative therapy for cancer treatment can cause severe oral mucositis.
  • Oral mucositis significantly impacts patient quality of life and treatment adherence.
  • Palifermin offers a targeted therapeutic approach for managing treatment-related toxicities.

Purpose:

  • To evaluate the efficacy of Palifermin in preventing and treating oral mucositis.
  • To assess the safety profile of Palifermin in patients undergoing intensive cancer therapies.
  • To understand the mechanism of action of Palifermin as a keratinocyte growth factor.

Summary:

  • Palifermin, a recombinant human keratinocyte growth factor (KGF), is produced using recombinant-DNA technology in Escherichia coli.
  • Clinical studies demonstrate Palifermin's protective effect against oral mucositis in adults undergoing myeloablative therapy.

Related Experiment Videos

  • The substance has shown promise in mitigating a common and debilitating side effect of cancer treatment.

    • Impact:

    • Palifermin represents a significant advancement in supportive care for cancer patients.
    • Improved management of oral mucositis can lead to better treatment outcomes and patient well-being.
    • Further research is needed to fully elucidate the long-term safety and efficacy of Palifermin.